Cargando…

Insights from the AQUA Registry: a retrospective study of anticholinergic polypharmacy in the United States

BACKGROUND: Anticholinergic (ACH) burden is a risk factor for negative health outcomes among older adults. Several medications contribute to ACH burden, including antimuscarinics used to manage overactive bladder (OAB). OBJECTIVES: This study aimed to understand the extent of ACH burden in an OAB po...

Descripción completa

Detalles Bibliográficos
Autores principales: Cooperberg, Matthew R., Mbassa, Rachel, Walker, David, Meeks, William, Lockefeer, Amy, Jiang, Baoguo, Li, Tina, Johnston, Karissa, Fang, Raymond
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871979/
https://www.ncbi.nlm.nih.gov/pubmed/36703880
http://dx.doi.org/10.1177/17562872221150572
_version_ 1784877302540140544
author Cooperberg, Matthew R.
Mbassa, Rachel
Walker, David
Meeks, William
Lockefeer, Amy
Jiang, Baoguo
Li, Tina
Johnston, Karissa
Fang, Raymond
author_facet Cooperberg, Matthew R.
Mbassa, Rachel
Walker, David
Meeks, William
Lockefeer, Amy
Jiang, Baoguo
Li, Tina
Johnston, Karissa
Fang, Raymond
author_sort Cooperberg, Matthew R.
collection PubMed
description BACKGROUND: Anticholinergic (ACH) burden is a risk factor for negative health outcomes among older adults. Several medications contribute to ACH burden, including antimuscarinics used to manage overactive bladder (OAB). OBJECTIVES: This study aimed to understand the extent of ACH burden in an OAB population in the United States. DESIGN: Non-interventional retrospective analysis. METHODS: Adults with OAB whose care providers participated in the American Urological Association Quality (AQUA) Registry between 2014 and 2020 were included in this study. An adapted version of the Pharmacy Quality Alliance (PQA) measure of anticholinergic polypharmacy (poly-ACH) was used to assess ACH burden. The primary outcome was the annual prevalence of poly-ACH, and a secondary outcome was the percentage of patients taking 0, 1, 2, 3, 4, or ⩾ 5 ACH medications by calendar year. Analyses were stratified by age category at diagnosis and sex. RESULTS: The sample comprised 552,840 patients with OAB. The mean age at initial OAB diagnosis was 65.7 years (58.2% male; 57.4% white). Prevalence of poly-ACH was highest in 2015 (3.7%) and lowest in 2020 (1.9%). Patients prescribed no ACH medications made up the largest proportion of each cohort, while those prescribed five or more comprised the smallest. The trend of decreasing proportions of patients taking increasing numbers of ACH medications was consistent. The proportion of patients prescribed no ACH medications increased from 63.3% in 2014 to 74.6% in 2020. The percentage of those prescribed three or more ACHs remained largely unchanged. Poly-ACH was highest among younger individuals (< 65 years of age) and females; temporal trends were similar overall and within each age and sex stratum. CONCLUSION: In this study, poly-ACH in patients with OAB was relatively infrequent and decreased over the study period. Further evaluation of poly-ACH is needed to assess whether the study findings reflect increased awareness of the negative effects of poly-ACH.
format Online
Article
Text
id pubmed-9871979
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-98719792023-01-25 Insights from the AQUA Registry: a retrospective study of anticholinergic polypharmacy in the United States Cooperberg, Matthew R. Mbassa, Rachel Walker, David Meeks, William Lockefeer, Amy Jiang, Baoguo Li, Tina Johnston, Karissa Fang, Raymond Ther Adv Urol Original Research BACKGROUND: Anticholinergic (ACH) burden is a risk factor for negative health outcomes among older adults. Several medications contribute to ACH burden, including antimuscarinics used to manage overactive bladder (OAB). OBJECTIVES: This study aimed to understand the extent of ACH burden in an OAB population in the United States. DESIGN: Non-interventional retrospective analysis. METHODS: Adults with OAB whose care providers participated in the American Urological Association Quality (AQUA) Registry between 2014 and 2020 were included in this study. An adapted version of the Pharmacy Quality Alliance (PQA) measure of anticholinergic polypharmacy (poly-ACH) was used to assess ACH burden. The primary outcome was the annual prevalence of poly-ACH, and a secondary outcome was the percentage of patients taking 0, 1, 2, 3, 4, or ⩾ 5 ACH medications by calendar year. Analyses were stratified by age category at diagnosis and sex. RESULTS: The sample comprised 552,840 patients with OAB. The mean age at initial OAB diagnosis was 65.7 years (58.2% male; 57.4% white). Prevalence of poly-ACH was highest in 2015 (3.7%) and lowest in 2020 (1.9%). Patients prescribed no ACH medications made up the largest proportion of each cohort, while those prescribed five or more comprised the smallest. The trend of decreasing proportions of patients taking increasing numbers of ACH medications was consistent. The proportion of patients prescribed no ACH medications increased from 63.3% in 2014 to 74.6% in 2020. The percentage of those prescribed three or more ACHs remained largely unchanged. Poly-ACH was highest among younger individuals (< 65 years of age) and females; temporal trends were similar overall and within each age and sex stratum. CONCLUSION: In this study, poly-ACH in patients with OAB was relatively infrequent and decreased over the study period. Further evaluation of poly-ACH is needed to assess whether the study findings reflect increased awareness of the negative effects of poly-ACH. SAGE Publications 2023-01-19 /pmc/articles/PMC9871979/ /pubmed/36703880 http://dx.doi.org/10.1177/17562872221150572 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Cooperberg, Matthew R.
Mbassa, Rachel
Walker, David
Meeks, William
Lockefeer, Amy
Jiang, Baoguo
Li, Tina
Johnston, Karissa
Fang, Raymond
Insights from the AQUA Registry: a retrospective study of anticholinergic polypharmacy in the United States
title Insights from the AQUA Registry: a retrospective study of anticholinergic polypharmacy in the United States
title_full Insights from the AQUA Registry: a retrospective study of anticholinergic polypharmacy in the United States
title_fullStr Insights from the AQUA Registry: a retrospective study of anticholinergic polypharmacy in the United States
title_full_unstemmed Insights from the AQUA Registry: a retrospective study of anticholinergic polypharmacy in the United States
title_short Insights from the AQUA Registry: a retrospective study of anticholinergic polypharmacy in the United States
title_sort insights from the aqua registry: a retrospective study of anticholinergic polypharmacy in the united states
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871979/
https://www.ncbi.nlm.nih.gov/pubmed/36703880
http://dx.doi.org/10.1177/17562872221150572
work_keys_str_mv AT cooperbergmatthewr insightsfromtheaquaregistryaretrospectivestudyofanticholinergicpolypharmacyintheunitedstates
AT mbassarachel insightsfromtheaquaregistryaretrospectivestudyofanticholinergicpolypharmacyintheunitedstates
AT walkerdavid insightsfromtheaquaregistryaretrospectivestudyofanticholinergicpolypharmacyintheunitedstates
AT meekswilliam insightsfromtheaquaregistryaretrospectivestudyofanticholinergicpolypharmacyintheunitedstates
AT lockefeeramy insightsfromtheaquaregistryaretrospectivestudyofanticholinergicpolypharmacyintheunitedstates
AT jiangbaoguo insightsfromtheaquaregistryaretrospectivestudyofanticholinergicpolypharmacyintheunitedstates
AT litina insightsfromtheaquaregistryaretrospectivestudyofanticholinergicpolypharmacyintheunitedstates
AT johnstonkarissa insightsfromtheaquaregistryaretrospectivestudyofanticholinergicpolypharmacyintheunitedstates
AT fangraymond insightsfromtheaquaregistryaretrospectivestudyofanticholinergicpolypharmacyintheunitedstates